Adaptimmune Therapeutics plc Capital Reinvestment Ratio

Latest as of June 2024: 0.02x

Adaptimmune Therapeutics plc capital reinvestment ratio. Adaptimmune Therapeutics plc (473A) has a Capital Reinvestment Ratio of 0.02x as of June 2024, meaning it reinvests 0% of its operating cash flow (€47.40 Million) in capital expenditures (€754.00K). Check Adaptimmune Therapeutics plc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.

Capital Reinvestment Ratio

0.02x

Capex / Operating Cash Flow

Operating Cash Flow

€47.40 Million

EUR

Capital Expenditures

€754.00K

EUR

Data as of

Jun 2024

Most recent filing

Capital Reinvestment Ratio of Adaptimmune Therapeutics plc (2021–2021)

Capital reinvestment ratio of Adaptimmune Therapeutics plc from 2021 to 2021. This chart tracks Adaptimmune Therapeutics plc's Capital Reinvestment Ratio across 1 annual periods. Also explore 473A net assets growth trend to track the company's year-over-year net asset growth rate.

Adaptimmune Therapeutics plc Capital Reinvestment Ratio by Year (2021–2021)

Adaptimmune Therapeutics plc capital reinvestment ratio by year from 2021 to 2021. For the full cash flow conversion analysis, see Adaptimmune Therapeutics plc cash conversion from operations.

Year	Reinvestment Ratio	Operating CF (EUR)	Capital Expenditures	YoY Change
2021	0.80x	€10.73 Million	€8.57 Million	—

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow